QualityStocks would like to highlight Threshold Pharmaceuticals, Inc. (NASDAQ: THLD). Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in micro-environments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, it is building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.
In the company’s news Friday,
Threshold Pharmaceuticals Inc. announced its ongoing phase III clinical trial results for its clinical stage hypoxia-activated pro-drug, TH-302, which were presented at the Connective Tissue Oncology Society (CTOS) Meeting in Chicago.
Sant P. Chawla, M.D., of the Sarcoma Oncology Center in Santa Monica and principal investigator for the study, gave the oral presentation summarizing the phase II results from the company’s fully enrolled 403 trial, which was comprised of patients with metastatic or locally advanced unresectable soft tissue sarcoma who were not previously received chemotherapy outside of the adjuvant or neoadjuvant setting. The trial treated patients at the TH-302 maximum tolerated dose to investigate the candidate in combination with doxorubicin.
“The data from the complete set of patients in the large phase II portion of our study of TH-302 in combination with standard doxorubicin in soft tissue sarcoma patients is impressive,” Dr. Chawla stated in the press release. “Most notable, the data suggest a sizable improvement in efficacy over conventional doxorubicin alone. Combined with its tolerability, the regimen has the potential to establish a new standard-of-care for the treatment of soft tissue sarcomas and provides ample justification for pursuing the registration of TH-302 in the ongoing phase III trial comparing TH-302 plus doxorubicin versus doxorubicin alone.”
The company reports that 91 patients were included in the analyses, including 89 patients with at least one evaluable post-treatment tumor assessment. Data demonstrates two complete responses; 30 partial responses; 43 patients with stable disease for an overall response rate of 36%; and a stable disease or better rate of 84%.
In February 2011, Threshold Pharmaceuticals reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of the phase III study, which includes a primary efficacy endpoint of overall survival.
The 403 trial is the basis for the ongoing pivotal phase III study designed to compare the same regimen investigated in the phase II portion of the 403 study against single agent doxorubicin.
About QualityStocks:
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
